Tysabri hit with fourth PML case this year
This article was originally published in Scrip
Executive Summary
Biogen Idecand Elanhave notified regulators of a new case of progressive multifocal leucoencephalopathy (PML) in a patient who had been receiving their drug Tysabri (natalizumab) for 26 months for the treatment of multiple sclerosis.